Anokion SA plans to start enrolling participants in the multiple ascending dose portion of their MoveS-it clinical trial assessing ANK-700 for the treatment of multiple sclerosis (MS), according to a press release from the company.

MoveS-it is a randomized, double-blind, placebo-controlled phase 1 study that aims to evaluate the safety and tolerability of ANK-700 in patients with relapsing-remitting MS. The trial has 2 parts. In the first, patients will receive a single dose of ANK-700, and they will receive 3 doses of either ANK-700 or placebo in the second.

The primary outcome measure is the incidence and severity of treatment-emergent adverse events. Secondary outcome measures are the geometric mean of maximum plasma concentration of the treatment and the area under the plasma concentration-time curve from time 0 days to the last measurable time point.

Continue Reading

Read more about the MS diagnosis

The trial is open for recruitment for patients with relapsing-remitting MS aged 18 to 55 years in Colorado, Ohio, Pennsylvania, Tennessee, Texas, and Washington. Its estimated completion date is December 2023.

ANK-700 is a previously identified myelin antigen that drives MS. The antigen is delivered to the liver using the company’s liver targeting glycosylation signature to re-educate the immune system to reduce neuroinflammation in the brain and spinal cord.

“Since our inception, Anokion has been focused on leveraging novel scientific insights in the biology of autoimmunity to create durable, disease-modifying medicines for individuals with autoimmune disorders that work by re-educating critical immune pathways in the body,” Deborah Geraghty, PhD, the chief executive officer of Anokion said.

So far, no safety signals were observed in the MoveS-it study. Initial results are expected in the second half of 2022.


Anokion announces progress across pipeline of novel autoimmune programs. News release. Anokion; January 6, 2022. 

Assessment of ANK-700 in patients with relapsing remitting multiple sclerosis (MoveS-it). US National Library of Medicine. Updated August 26, 2021. Accessed January 24, 2021.